SCOS is raising its advocacy voice on state and federal issues.

We are actively working to ensure that the voice of oncology in South Carolina is heard. Explore our website for the latest updates in oncology and healthcare-related legislation in South Carolina, discover SCOS' advocacy on the state and federal level, and more. 

SCOS values your input. Help us make a difference in our state. Do you know a South Carolina State Legislature member? Do you have an issue you want brought to the attention of the state legislature? Please contact us with all questions and comments.


  • 20 novel drugs from 19 different companies were approved for 15 different conditions.
  • In addition, 2 approvals were for new formulations of already marketed drugs—Onureg® (azacytidine) and Darzalex FasproTM (daratumumab and hyaluronidase-fihj).
  • For the first time ever, more than half of the approvals (11) were “accelerated” (i.e., based on intermediate endpoints). Continued approval for these drugs may depend on verification of clinical benefit.
  • Tyrosine kinase inhibitors constituted the largest single drug “type” (there were 7), while drug conjugates were the 2nd largest modality (4).
  • Approvals were about evenly divided between oral and infused/injected agents (9 and 11, respectively).
  • Seven of the approvals specify genetic alterations that should be incorporated into patient selection.
Download Overview

Legislative Updates

Under the Dome—Legislative Report

February 5, 2021

This week, the Senate and House of Representatives convened in statewide session (Senate in perfunctory session on Tuesday) to consider major legislation on the calendars, elect judges and continue focusing on subcommittee and full committee work. The Senate held extensive debate on H.3707, a funding bill addressing the distribution and administration of COVID-19 vaccines, along with S.516, a new bill which would move teachers and school staff to Phase 1a as “mission-critical workers” to receive vaccines with the caveat of all school districts offering 5-day-a-week in-person instruction by March 2.

Read Full Report

Federal Advocacy 

SCOS Joins Coalition Letter Urging Addition of the Cures 2.0 Concept Paper Title IV Provisions in the Next COVID-19 Relief Package

The South Carolina Oncology Society (SCOS) joined in a coalition letter to congressional leadership urging that Congress include the 21st Century Cures 2.0 concept paper, recently released by Representatives Diana DeGette and Fred Upton in upcoming legislation to further address the COVID-19 public health crisis. Specifically the letter urges leadership to include policy to provide Medicaid coverage of the routine care costs of clinical trials participation for patients with life-threatening conditions in every state. This critical protection is championed by Representatives Ben Ray Luján and Gus Bilirakis in the Clinical Treatment Act (H.R. 913).

Webinars & Webcasts

Archived Webinar: CMS Final 2020 Outpatient Prospective Payment System & Physician Fee Schedule Rules: What You Need to Know

ACCC members were invited to join legal experts and their ACCC colleagues for a one-hour overview and discussion about the Centers for Medicare & Medicaid Services (CMS) final CY 2020 OPPS and PFS rules. The webinar covered key proposals the agency has finalized under the OPPS that will affect next year’s payments for 340B hospitals, excepted off-campus provider-based departments (PBDs), as well as updates to the administration's pricing transparency and drug pricing reform efforts. A recording of this webinar, presentation slides, and rule summaries are available to ACCC members.  

ACCC members can access summaries of the final rules here. [Requires Login] Also available, a summary of selected provisions of the CY2020 Hospital Price Transparency Requirements for Hospitals to Make Standard Charges Public final rule. [Requires Login]

View On-Demand Webinar Replay (Requires Login)

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us